FLGT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
FLGT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Fulgent Genetics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $1,136.1 Mil. Fulgent Genetics's Total Assets for the quarter that ended in Dec. 2023 was $1,235.3 Mil. Therefore, Fulgent Genetics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.92.
The historical rank and industry rank for Fulgent Genetics's Equity-to-Asset or its related term are showing as below:
During the past 10 years, the highest Equity to Asset Ratio of Fulgent Genetics was 0.95. The lowest was 0.79. And the median was 0.92.
The historical data trend for Fulgent Genetics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fulgent Genetics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Equity-to-Asset | Get a 7-Day Free Trial | 0.93 | 0.81 | 0.91 | 0.91 | 0.92 |
Fulgent Genetics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Equity-to-Asset | Get a 7-Day Free Trial | 0.91 | 0.92 | 0.93 | 0.93 | 0.92 |
For the Diagnostics & Research subindustry, Fulgent Genetics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, Fulgent Genetics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Fulgent Genetics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Fulgent Genetics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Equity to Asset (A: Dec. 2023 ) | = | Total Stockholders Equity | / | Total Assets |
= | 1136.101 | / | 1235.328 | |
= | 0.92 |
Fulgent Genetics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as
Equity to Asset (Q: Dec. 2023 ) | = | Total Stockholders Equity | / | Total Assets |
= | 1136.101 | / | 1235.328 | |
= | 0.92 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fulgent Genetics (NAS:FLGT) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Thank you for viewing the detailed overview of Fulgent Genetics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Jian Xie | officer: Chief Operating Officer | C/O FULGENT GENETICS, INC., 4399 SANTA ANITA AVE, EL MONTE CA 91731 |
Hanlin Gao | 10 percent owner, officer: Chief Scientific Officer | 4399 SANTA ANITA AVE., EL MONTE CA 91731 |
Paul Kim | officer: CFO and Treasurer | 4399 SANTA ANITA AVE, EL MONTE CA 91731 |
Regina E Groves | director | 5751 COPLEY DRIVE, SAN DIEGO CA 92111 |
Leonard E Post | director | |
Michael Nohaile | director | C/O BIO AI ACCELERATION COMPANY, 20 UNIVERSITY AVENUE, CAMBRIDGE MA 02138 |
John C Bolger | director | 4978 SANTA ANITA AVENUE, SUITE 205, TEMPLE CITY CA 91780 |
Ming Hsieh Trust | 10 percent owner | 4399 SANTA ANITA AVE., EL MONTE CA 91731 |
Linda Marsh | director | 100 N. STONEMAN AVE., ROOM 200, ALHAMBRA CA 91801 |
Ming Hsieh | director, 10 percent owner, officer: President and CEO | 4399 SANTA ANITA AVE., EL MONTE CA 91731 |
Fulgent Genetics, Inc. | director | 4399 SANTA ANITA AVE, EL MONTE CA 91731 |
Yun Yen | director | 1301 OAKLAWN ROAD, ARCADIA CA 91006 |
James Mulay | director | 6521 THOROUGHBRED LOOP, ODESSA FL 33556 |
Xi Long Usa, Inc. | 10 percent owner | #6 XINRUI RD., SCIENCE CITY, LUOGANG DISTRICT, GUANGZHOU CITY F4 510663 |
From GuruFocus
By Tiesvg Tiesvg • 12-27-2022
By PRNewswire PRNewswire • 11-21-2022
By Value_Insider Value_Insider • 11-19-2022
By Business Wire • 10-17-2023
By Business Wire Business Wire • 02-28-2023
By Business Wire Business Wire • 04-20-2023
By Business Wire Business Wire • 06-05-2023
By Business Wire Business Wire • 02-14-2023
By Business Wire Business Wire • 01-03-2023
By Stock market mentor Stock market mentor • 01-18-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.